EYPT, US30233G2093

EyePoint Pharmaceuticals stock fell 3.08 percent as LUCIA nears

Published on 10/06/2026 at 09:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EyePoint Pharmaceuticals stock was last at USD 3.15 on October 5, while 11 analysts set a USD 25.70 average target. Q2 revenue reached USD 507,000.

EYPT, US30233G2093, Illustration mit AI erstellt.

EyePoint Pharmaceuticals (ISIN US30233G2093) stock was last at USD 3.15 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, down 3.08 percent from the prior session. The latest clinical readout keeps attention on DURAVYU and the pending LUCIA study, after new October 5 coverage detailed both the setback and the drug's potential treatment advantage.

LUGANO cuts injection burden 42 percent

According to Ophthalmology Times on October 5, 2026, DURAVYU missed the LUGANO trial's primary non-inferiority endpoint in wet age-related macular degeneration. The study nevertheless produced a 42 percent reduction in treatment burden after the loading phase, with 80 percent of patients receiving zero or one supplemental injection during the year.

The trial included 432 randomized patients and compared a 2.7 mg vorolanib insert dosed every six months with aflibercept administered every eight weeks. The difference in visual acuity gain was 3.8 letters, while the source said nine patients who lost vision for causes other than wet AMD were concentrated in the DURAVYU arm.

Q2 revenue reaches USD 507,000

EyePoint's second-quarter 2026 figures show the commercial and financial pressure behind the development program. MarketBeat reported that quarterly revenue was USD 507,000 in Q2 2026, above the USD 450,000 analyst estimate. Quarterly EPS was a loss of USD 1.09, missing the USD 1.01 consensus by USD 0.08.

The next pivotal test is LUCIA, the paired Phase 3 study. StockTitan reported on September 10, 2026 that EyePoint expected LUCIA topline data in Q4 2026 and planned a pre-NDA meeting with the FDA in Q4 2026. A positive result is a condition for the company's targeted first-half 2027 wet AMD filing.

Consensus target towers over price

Analyst expectations remain unusually wide relative to the October 5 quotation. MarketBeat said 11 research firms carried a consensus Hold rating, comprising six holds, four buys and one sell, with an average 12-month target of USD 25.70. That target lies 715.9 percent above the October 5 price of USD 3.15.

The contrast defines the risk profile: the market is valuing a company whose lead program missed its first primary endpoint, while the consensus still reflects potential value from a successful LUCIA result and a future regulatory filing.

EyePoint stock stays near yearly low

EyePoint stock was last at USD 3.15 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with a session range of USD 3.05 to USD 3.26. Its 52-week range was USD 3.05 to USD 19.11, and market capitalization stood at USD 264.1 million.